Novo Nordisk's German Pill Launch Collides With a Pipeline Story Investors Aren't Buying
Published on 09/02/2026 at 03:02 | Editorial boerse-global.de
The Wegovy tablet has finally reached a European pharmacy shelf, yet the share price reaction tells a quieter story than the commercial milestone might suggest. Novo Nordisk's oral semaglutide went on sale in Germany on Wednesday — its first EU market — but the stock sits roughly 28 percent below its January peak of €54.86, a gap that speaks to how far the company's growth premium has already deflated.
At €39.37, the shares trade about 5.7 percent under their 50-day moving average of €41.74. The muted reception is striking given the scale of the opportunity: Germany counts some 13 million potential patients with obesity or overweight plus comorbidities, and Novo Nordisk controls roughly 90 percent of the global oral obesity-drug market as of August. The tablet, priced between €170 and €280 per month, will be paid entirely out of pocket — German insurers won't reimburse it, a structural quirk that cuts both ways.
A Self-Pay Market With No Reimbursement Fight
The absence of reimbursement negotiations is, in one sense, a gift. Novo Nordisk can set prices without the usual tug-of-war with cost regulators, and pharmacies have already stocked up. The company insists supply is ample — a pointed contrast to the shortages that have dogged Ozempic and Wegovy injections in the past. If demand meets expectations, the German rollout could become the template for other EU markets, reviving a growth narrative that has lost its shine.
The clinical case is solid. In the OASIS-4 registration study, patients with comorbidities lost an average of 17 percent of their body weight over 64 weeks on a daily 25-milligram dose — figures competitive with the injectable version. But the self-pay model carries a hidden risk: adherence. When patients stop taking the drug, hunger returns; in one documented case, 20 of 30 lost kilograms came back. At up to €280 a month from the patient's own wallet, that's a real dropout trigger, and recurring revenue dies with it.
A Pipeline Spreading Its Bets
Behind the commercial push, Novo Nordisk is quietly assembling a broader research web — one that suggests management is hedging against over-reliance on the next Wegovy generation. On August 12, the company kicked off the OASIS-5 late-stage study, testing lower doses of the oral pill in 450 participants across 62 centers in the US and Europe. Results aren't expected until April 2028 — a long runway that the company appears willing to fund despite the market's skepticism.
While Novo Nordisk bets on long-term pipeline timelines, workplace safety demands attention in the here and now. Many employers overlook gaps in their risk documentation until an incident forces the issue. A free toolkit with 41 ready-to-use templates and checklists helps you document hazards properly and stay compliant. Download the free Risk Assessment Toolkit
Days later, on August 20, Novonesis announced that microbiome-based preparations developed jointly with Novo Nordisk — intended as add-ons to GLP-1 obesity drugs — should yield first data in the second half of 2027. Then Lexicon Pharmaceuticals confirmed on August 24 that it had received a milestone payment from Novo Nordisk tied to progress on LX9851, a candidate targeting obesity and metabolic disorders. Add the July partnership with Vivani Medical to test an implant for automated Wegovy delivery, and a pattern emerges: three partners, three mechanisms, one deliberate strategy of spreading pipeline risk.
Analysts Can't Agree, and the Stock Pays for It
The market's confusion about this approach is visible in the analyst community's rare divergence. JPMorgan's Richard Vosser raised his price target from 250 to 275 Danish kroner in late August but kept a Neutral rating — a signal pointing up without conviction. Two days later, Deutsche Bank moved the opposite way, cutting the stock from Hold to Sell with a 265-krone target. Nearly identical target ranges, diametrically opposed recommendations — a snapshot of an investment case in limbo.
The technicals offer little clarity. At €39.01 in recent trading, the stock sits roughly 6.5 percent below its 50-day average, with an RSI near 41 — neither oversold nor overbought, just directionless. The one bright spot for the bulls: Novo Nordisk still holds an EU approval lead in oral GLP-1s, and Eli Lilly's Retatrutide remains in the pipeline without a European green light. Until that changes, the Danish company can exercise pricing power in a self-pay market largely uncontested.
The Test Ahead
The near-term question is simpler than the pipeline calculus: Will German patients actually keep paying? The first weeks of pharmacy sales will offer early signals on demand, and whether the company holds to its supply commitments. A strong start could reframe the story as a blueprint for the rest of Europe; weak adherence or a faster-than-expected Lilly advance would likely deepen the discount already priced into the shares.
For now, the market is demanding tangible proof — regulatory steps, concrete sales data — rather than promises of microbiome projects with 2027 timelines or implants in early development. The German launch is the most immediate evidence available, and investors are watching it closely.
